ArticleLeukemia2005
CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis.
Article in Leukemia, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Prognostic impact of invariant natural killer T cells in solid and hematological tumors; systematic review and meta-analysis.Cancer biomarkers : section A of Disease markers · 2024Pooled it
- Natural Killer T Cell Function in Lymphoma Patients.Biomolecules · 2026Article
- Article
- Exploiting innate immunity for cancer immunotherapy.Molecular cancer · 2023Review
- Review
- Article
- CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2021Article
- Translating Unconventional T Cells and Their Roles in Leukemia Antitumor Immunity.Journal of immunology research · 2021Review
- Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting.Cancer cell · 2018Article
- Possible Therapeutic Application of Targeting Type II Natural Killer T Cell-Mediated Suppression of Tumor Immunity.Frontiers in immunology · 2018Review
- Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies.Frontiers in immunology · 2017Review
- Immunotherapeutic strategies targeting natural killer T cell responses in cancer.Immunogenetics · 2016Review
- The regulatory role of invariant NKT cells in tumor immunity.Cancer immunology research · 2015Review
- CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival.Journal of clinical pathology · 2015Article
- Adoptive T Cell Therapy Targeting CD1 and MR1.Frontiers in immunology · 2015Review
- Role and regulation of CD1d in normal and pathological B cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Review
- CD1d levels in peripheral blood of patients with acute myeloid leukemia and acute lymphoblastic leukemia.Oncology letters · 2014Article
- Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells.Clinical immunology (Orlando, Fla.) · 2013Article
- The role of natural killer T cells in B cell malignancies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Review
- Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia.Medical oncology (Northwood, London, England) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lymphoblastic leukemia (ALL) is the most frequent malignancy of childhood. Although therapeutical advances have been achieved, some ALL subgroups still fare poorly. CD1d is a monomorphic molecule that provides a suitable target for immunotherapy in view of the characterization of a glycolipid, alpha-galactosylceramide (alpha-GalCer), capable of being presented to CD1d-restricted T cells with cytotoxic potential. We investigated CD1d expression in 80 pediatric B-cell precursor (BCP) ALL cases defined according to immunophenotype, cytogenetic features and age at onset. CD1d was detected on ALL cells in 15% of the patients. CD1d+ ALLs were significantly associated with infant leukemia, pro-B phenotype and mixed-lineage leukemia (MLL)/AF4 gene rearrangement. Accordingly, overall survival of patients with CD1d+ ALL was significantly shorter. CD1d+ leukemic blasts were able to present alpha-GalCer via CD1d to cytotoxic CD1d-restricted T cells, which induced apoptosis of ALL cells that was inhibited by mAb to CD1d. CD1d+ blasts loaded with alpha-GalCer elicited cytokine secretion by CD1d-restricted T cells. Analysis of bone marrow (BM) cells derived from normal donors revealed that CD19+/CD1d+ cells were mostly mature B lymphocytes. However, a minority of BCPs expressed CD1d. Thus, expression of CD1d in ALL cases heralds an adverse prognosis but may provide a therapeutic tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.